CenExel has been serving the pharmaceutical industry since 1986, and we are proud to have developed preferred provider agreements with major pharmaceutical companies and CROs.
Our Centers of Excellence emphasize specific therapeutic areas to concentrate expertise and drive reliable results. We focus on delivering quality research through centralized SOPs and real-time data surveillance. The centralization of our budgeting and contracting allows for rapid study start-up in trials involving multiple Centers of Excellence. We empower qualified people and highly-experienced clinical research managers with a history of success. Our world-renowned principal investigators offer unparalleled medical and scientific consulting services in both the design and execution of clinical trials. By combining local and centralized recruiting, we consistently surpass our patient recruitment goals.
Our research Centers of Excellence represent the most experienced psychiatric clinical research sites in the United States. We have conducted more than 1,000 studies (pediatric, adolescent, adult, and senior) in schizophrenia, bipolar disorder, depression, anxiety, and other psychiatric indications, spanning a broad spectrum of Phase I through Phase IV trials. Our established network in metropolitan areas enables healthy diversity in recruitment.
Our principal investigators have a combined 200+ years of experience and are regularly consulted by sponsors as key opinion leaders in clinical development programs of new chemical entities. A key differentiator is their breadth of experience in the design and practical implementation of clinical research studies. We provide state-of-the-art research-oriented psychiatric care in our dedicated inpatient clinical research units, comprising nearly 500 beds. We provide first-class medical care while conducting essential clinical research to advance life-changing medicines.
Our Centers of Excellence and expert team of industry-leading physician principal investigators are closely collaborating with pharmaceutical sponsors through all stages of vaccine clinical research development, from pre-study protocol design through successful trial execution. We have wide-ranging adult, pediatric, and elderly vaccine clinical trial experience from first-in-human (FIH), Phase I vaccine trial conduct, all the way through to Phase III pivotal trials and subsequent regulatory approval. Our Centers offer diverse recruitment due to strategic locations in densely populated areas.
Our vaccine clinical research experience comprises a wide spectrum of infectious and biodefense indications, including seasonal and pandemic influenza, pneumococcal, ZIKA, Ebola, HIV, Cholera, Smallpox, Meningococcal Group B, Staphylococcus-aureus, C. difficile, Typhoid, Botulism, Anthrax, Rabies, West Nile Virus, RSV, Noro Virus, HPV, HSV-2, RSV, and many others.
Our facilities also offer real-time peripheral blood mononuclear cell (PBMC) isolation, which allows for efficacy evaluation of cell-mediated immunity. CenExel RCA earned the designation of “Best Clinical Trial Site” at the World Vaccine Congress 2018.
Our Centers are at the forefront of Phase I – IV clinical trials in neurology in the United States, having conducted more than 150 clinical protocols in neurology over the past 5 years, all with diverse enrollment demographics. We are experts in recruiting and supporting studies for all age ranges.
Our clinical coordinators, clinicians, and principal investigators are highly trained and experienced in the areas of Alzheimer’s Disease, Parkinson’s Disease, Dementia, Migraines, and Multiple Sclerosis, as well as many others. Our expert clinical raters regularly participate in training to assure the highest quality and reliability of these critical endpoint assessments.
Our Centers of Excellence are the world’s foremost experts in the design, execution, analysis, and interpretation of clinical studies in Post-Operative Acute Pain. CenExel JBR is the premier dental pain clinical research site in the world, having conducted more than 100 clinical trials on 15,000 patients (pediatric through senior), using the 3rd molar extraction model for development of new and safer analgesic medications.
Our Centers are the leaders in hard and soft tissue analgesic research sites in the U.S., using the bunionectomy, hernia, abdominoplasty, and total knee arthroplasty pain models. We have comprehensive Phase I through IV experience in pain-related clinical trials, reaching diverse demographics with our strategic locations.
Our team members are extensively prepared by using proprietary analgesic rater training methodologies to assure the highest quality of clinical research data. Our board-certified principal investigator physicians are clinical experts and key opinion leaders. Our Analgesic Scientific Advisory Board includes top experts in analgesic drug development.
CenExel ACT, our research Center of Excellence in Anaheim, California is a leading site in the United States in conducting Japanese- and Ethnic-Bridging studies. In the past three years, we’ve enrolled more than 1,000 patients in these trials, with most of these as single center studies. Our clinical team is comprised of native Japanese clinical coordinators and patient recruitment specialists. We have strong connections in the community, enabling access to first-, second-, and even third-generation subjects.
From board-certified neurologists and sleep physicians to registered polysomnography (PSG) technicians and PSG scorers, our experienced staff have conducted clinical trials for pediatric, adolescent, adult, and senior populations. Our medical research expertise spans insomnia, sleep apnea, shift work disorder, jet lag, restless leg syndrome, narcolepsy, and driving simulations, among other areas. By using state-of-the-art technology and ensuring each patient receives quality amenities, we offer patients a comfortable and serene environment while maintaining an appropriate setting and ample resources for our staff.
Phase I & Special Populations
All our Centers of Excellence have a long history of Phase I experience and host essential resources on-site to accommodate Phase I needs. Combined, we have 250,000 square feet in our facilities and nearly 500 beds available. Our Centers are also located in geographically and demographically diverse areas, reaching roughly 40 million individuals within close proximity to one of our metropolitan facilities.
Ready to learn more?
Find out how our engagement and expertise can help you obtain your clinical research results, on-time and on-budget.